| Identification | Back Directory | [Name]
DAPIVIRINE,4-[[4-(2,4,6-TRIMETHYLPHENYL)AMINO]PYRIMIDIN-2-YL]AMINO]BENZONITRILE | [CAS]
244767-67-7 | [Synonyms]
CS-566
R 147681
Dapivirine
TMC 120R147681
Dapivirine, >=98%
Dapivirine,TMC-120
TMC 120R147681 Dapivirine
Dapivirine TMC120, AIDS-105293
Dapivirine,TMC-120, 244767-67-7
Dapivirine - R 147681 | TMC 120
R 147681; TMC 120; TMC 120; R147681
DAPIVIRINE(TMC 120, TMC 120 R147681)
DAPIVIRINE (TMC120);R 147681; TMC 120
4-(4-(MESITYLAMINO)PYRIMIDIN-2-YLAMINO)BENZONITRILE
4-[[4-(2,4,6-TRIMETHYLPHENYL)AMINO]PYRIMIDIN-2-YL]AMINO]BENZONITRILE
4-[[4-[(2,4,6-TriMethylphenyl)aMino]-2-pyriMidinyl]aMino]benzonitrile
Benzonitrile, 4-[[4-[(2,4,6-triMethylphenyl)aMino]-2-pyriMidinyl]aMino]-
DAPIVIRINE,4-[[4-(2,4,6-TRIMETHYLPHENYL)AMINO]PYRIMIDIN-2-YL]AMINO]BENZONITRILE
DAPIVIRINE,4-[[4-(2,4,6-TRIMETHYLPHENYL)AMINO]PYRIMIDIN-2-YL]AMINO]BENZONITRILE USP/EP/BP
Dapivirine 4-[[4-[(2,4,6-Trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile | [Molecular Formula]
C20H19N5 | [MDL Number]
MFCD09833899 | [MOL File]
244767-67-7.mol | [Molecular Weight]
329.4 |
| Chemical Properties | Back Directory | [Melting point ]
218-222°C | [Boiling point ]
557.9±60.0 °C(Predicted) | [density ]
1.23±0.1 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Inert atmosphere,2-8°C | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
4.74±0.10(Predicted) | [color ]
Off-White to Light Beige | [InChI]
1S/C20H19N5/c1-13-10-14(2)19(15(3)11-13)24-18-8-9-22-20(25-18)23-17-6-4-16(12-21)5-7-17/h4-11H,1-3H3,(H2,22,23,24,25) | [InChIKey]
ILAYIAGXTHKHNT-UHFFFAOYSA-N | [SMILES]
CC1=CC(=C(C(=C1)C)NC2=NC(=NC=C2)NC3=CC=C(C=C3)C#N)C |
| Hazard Information | Back Directory | [Chemical Properties]
Light Beige Solid | [Uses]
Non-nucleoside Reverse Transcriptase inhibitor. An antiviral agent | [Biological Activity]
Dapivirine is a diarylpyrimidine non-nucleoside reverse transcriptase inhibitor and has activity against wild-type virus strains and strains harboring different NNRTI resistance-inducing mutations. | [in vivo]
Dapivirine (16 mg/kg, once every 3 days for 12 days) exhibits potent antitumor activity in human glioblastoma models in mice[1].
Dapivirine has been shown to have a half-life in the range of 65 to 90 h[4].
| Animal Model: | U87 cells were subcutaneously injected into the nude mice[1]. | | Dosage: | 16 mg/kg. | | Administration: | Once every 3 days for 12 days. | | Result: | Significantly decreased the tumor volumes.
A significant decrease in Ki67 (a marker for proliferating cells that is overexpressed in many cancers) staining in sections of dapivirine-treated tumors compared to tumors from vehicle-treated mice.
|
| [target]
HIV reverse transcriptase | [IC 50]
HIV-1 |
|
|